

Thomas J Montine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3039890/publications.pdf>

Version: 2024-02-01

424
papers

58,869
citations

1893

102
h-index

1347

223
g-index

437
all docs

437
docs citations

437
times ranked

52680
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid Deployment of Whole Slide Imaging for Primary Diagnosis in Surgical Pathology at Stanford Medicine: Responding to Challenges of the COVID-19 Pandemic. Archives of Pathology and Laboratory Medicine, 2023, 147, 359-367.	2.5	1
2	Establishing a Data Science Unit in an Academic Medical Center: An Illustrative Model. Academic Medicine, 2022, 97, 69-75.	1.6	5
3	A Metabolomic Aging Clock Using Human Cerebrospinal Fluid. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 744-754.	3.6	19
4	Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer's Disease. Journal of Proteome Research, 2022, 21, 118-131.	3.7	15
5	Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy. European Journal of Medicinal Chemistry, 2022, 229, 114080.	5.5	19
6	Phenotypic Heterogeneity among GBA p.R202X Carriers in Lewy Body Spectrum Disorders. Biomedicines, 2022, 10, 160.	3.2	0
7	Mass Synaptometry: Applying Mass Cytometry to Single Synapse Analysis. Methods in Molecular Biology, 2022, 2417, 69-88.	0.9	4
8	Epigenomic priming of immune genes implicates oligodendroglia in multiple sclerosis susceptibility. Neuron, 2022, 110, 1193-1210.e13.	8.1	36
9	The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation. Brain Research, 2022, 1778, 147781.	2.2	7
10	Neuropathological lesions and their contribution to dementia and cognitive impairment in a heterogeneous clinical population. Alzheimer's and Dementia, 2022, 18, 2403-2412.	0.8	4
11	Putting Humpty Dumpty Back Together Again: What Does Protein Quantification Mean in Bottom-Up Proteomics?. Journal of Proteome Research, 2022, 21, 891-898.	3.7	35
12	Hemispheric Asymmetry and Atypical Lobar Progression of Alzheimer-Type Tauopathy. Journal of Neuropathology and Experimental Neurology, 2022, 81, 158-171.	1.7	2
13	Tracking Innate Immune Activation in a Mouse Model of Parkinson's Disease Using TREM1 and TSPO PET Tracers. Journal of Nuclear Medicine, 2022, 63, 1570-1578.	5.0	8
14	Predictive Modeling of Alzheimer's and Parkinson's Disease Using Metabolomic and Lipidomic Profiles from Cerebrospinal Fluid. Metabolites, 2022, 12, 277.	2.9	9
15	Cognitive resilience to three dementia-related neuropathologies in an oldest-old man: A case report from The 90+ Study. Neurobiology of Aging, 2022, 116, 12-15.	3.1	7
16	AI-enabled in silico immunohistochemical characterization for Alzheimer's disease. Cell Reports Methods, 2022, 2, 100191.	2.9	9
17	Discovery of 1 <i>H</i> -Pyrazole Biaryl Sulfonamides as Novel G2019S-LRRK2 Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2022, 13, 981-988.	2.8	6
18	Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathologica, 2022, 144, 27-44.	7.7	67

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 666-695.	1.7	22
20	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 776-785.	1.3	30
21	Cognitive Impairment in Older Adults and Therapeutic Strategies. <i>Pharmacological Reviews</i> , 2021, 73, 152-162.	16.0	24
22	Genetic Insights into Alzheimer's Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 351-376.	22.4	11
23	Angiotensin-converting enzyme 2 (ACE2) expression increases with age in patients requiring mechanical ventilation. <i>PLoS ONE</i> , 2021, 16, e0247060.	2.5	73
24	Collaborative Neuropathology Network Characterizing Outcomes of TBI (CONNECT-TBI). <i>Acta Neuropathologica Communications</i> , 2021, 9, 32.	5.2	13
25	Creatine transport and pathological changes in creatine transporter deficient mice. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 939-948.	3.6	7
26	Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying α -Synuclein-Containing Extracellular Vesicles. <i>Neurology</i> , 2021, 96, e2332-e2345.	1.1	18
27	The Delayed Neuropathological Consequences of Traumatic Brain Injury in a Community-Based Sample. <i>Frontiers in Neurology</i> , 2021, 12, 624696.	2.4	22
28	Enantiomers of 2-methylglutamate and 2-methylglutamine selectively impact mouse brain metabolism and behavior. <i>Scientific Reports</i> , 2021, 11, 8138.	3.3	3
29	Aging-related Alzheimer's disease-like neuropathology and functional decline in captive vervet monkeys (<i>Chlorocebus aethiops sabaeus</i>). <i>American Journal of Primatology</i> , 2021, 83, e23260.	1.7	16
30	Mass-tag barcoding for multiplexed analysis of human synaptosomes and other anuclear events. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 939-945.	1.5	7
31	Cognition at Each Stage of Lewy Body Disease with Co-occurring Alzheimer's Disease Pathology ¹ . <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1243-1256.	2.6	20
32	Gender differences in the assessment of depression in American Indian older adults: The Strong Heart Study. <i>Psychological Assessment</i> , 2021, 33, 574-579.	1.5	7
33	Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021, 43, 469-480.	1.3	10
34	Enantiomers of 4-aminopentanoic acid act as false GABAergic neurotransmitters and impact mouse behavior. <i>Journal of Neurochemistry</i> , 2021, 158, 1074-1082.	3.9	1
35	Diet Effects on Cerebrospinal Fluid Amino Acids Levels in Adults with Normal Cognition and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 843-853.	2.6	4
36	Isoform-specific dysregulation of AMP-activated protein kinase signaling in a non-human primate model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2021, 158, 105463.	4.4	9

#	ARTICLE	IF	CITATIONS
37	GATM and GAMT synthesize creatine locally throughout the mammalian body and within oligodendrocytes of the brain. <i>Brain Research</i> , 2021, 1770, 147627.	2.2	13
38	Relationships Between Sensorimotor Inhibition and Mobility in Older Adults With and Without Parkinson's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 630-637.	3.6	6
39	Clonal Hematopoiesis is Associated with Reduced Risk of Alzheimer's Disease. <i>Blood</i> , 2021, 138, 5-5.	1.4	15
40	Single-synapse analyses of Alzheimer's disease implicate pathologic tau, DJ1, CD47, and ApoE. <i>Science Advances</i> , 2021, 7, eabk0473.	10.3	14
41	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , 2020, 19, 71-80.	10.2	94
42	Cognitive Correlates of MRI-defined Cerebral Vascular Injury and Atrophy in Elderly American Indians: The Strong Heart Study. <i>Journal of the International Neuropsychological Society</i> , 2020, 26, 263-275.	1.8	17
43	Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. <i>Cell</i> , 2020, 183, 126-142.e17.	28.9	269
44	Risk of Transmissibility From Neurodegenerative Disease-Associated Proteins: Experimental Knowns and Unknowns. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 1141-1146.	1.7	24
45	Single-cell peripheral immunoprofiling of Alzheimer's and Parkinson's diseases. <i>Science Advances</i> , 2020, 6, .	10.3	29
46	Hallucinations and Development of Dementia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1643-1648.	2.8	7
47	Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer's and Parkinson's diseases. <i>Nature Genetics</i> , 2020, 52, 1158-1168.	21.4	217
48	Sensorimotor Inhibition and Mobility in Genetic Subgroups of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 893.	2.4	3
49	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1816-1830.	3.7	23
50	Multivariate prediction of dementia in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2020, 6, 20.	5.3	25
51	The inherent challenges of classifying senescence's Response. <i>Science</i> , 2020, 368, 595-596.	12.6	5
52	Positron Emission Tomography Imaging With [¹⁸ F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. <i>JAMA Neurology</i> , 2020, 77, 829.	9.0	244
53	Arterial spin labeling detects perfusion patterns related to motor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 76, 21-28.	2.2	10
54	Engineering monocyte/macrophage-specific glucocerebrosidase expression in human hematopoietic stem cells using genome editing. <i>Nature Communications</i> , 2020, 11, 3327.	12.8	28

#	ARTICLE	IF	CITATIONS
55	Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau. <i>Brain</i> , 2020, 143, 932-943.	7.6	49
56	Participant and Study Partner Reported Impact of Cognition on Functional Activities in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 61-69.	1.5	11
57	Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. <i>Nature Communications</i> , 2020, 11, 667.	12.8	246
58	Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. <i>Nature Medicine</i> , 2020, 26, 769-780.	30.7	547
59	Resting-State Cerebello-Cortical Dysfunction in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 594213.	2.4	11
60	Comparison of regional florbetapir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study. <i>EJNMMI Research</i> , 2020, 10, 65.	2.5	25
61	Effect of Dopaminergic Medications on Blood Oxygen Level-Dependent Variability and Functional Connectivity in Parkinson's Disease and Healthy Aging. <i>Brain Connectivity</i> , 2019, 9, 554-565.	1.7	6
62	The basis of cellular and regional vulnerability in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 138, 729-749.	7.7	73
63	Reply: LATE to the PART-y. <i>Brain</i> , 2019, 142, e48-e48.	7.6	11
64	Cognitive associations with comprehensive gait and static balance measures in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 104-110.	2.2	41
65	Sex differences in the genetic predictors of Alzheimer's pathology. <i>Brain</i> , 2019, 142, 2581-2589.	7.6	65
66	MIBI-TOF: A multiplexed imaging platform relates cellular phenotypes and tissue structure. <i>Science Advances</i> , 2019, 5, eaax5851.	10.3	252
67	To help aging populations, classify organismal senescence. <i>Science</i> , 2019, 366, 576-578.	12.6	42
68	Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures. <i>Clinical Parkinsonism & Related Disorders</i> , 2019, 1, 91-97.	0.9	22
69	"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia". <i>Alzheimer's and Dementia</i> , 2019, 15, 153-157.	0.8	23
70	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	2.2	15
71	Visuospatial functioning is associated with sleep disturbance and hallucinations in nondemented patients with Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2019, 41, 803-813.	1.3	10
72	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. <i>Brain</i> , 2019, 142, 1503-1527.	7.6	873

#	ARTICLE	IF	CITATIONS
73	Cognitive Performance in Parkinson's Disease in the Brain Health Registry. Journal of Alzheimer's Disease, 2019, 68, 1029-1038.	2.6	8
74	Concepts for brain aging: resistance, resilience, reserve, and compensation. Alzheimer's Research and Therapy, 2019, 11, 22.	6.2	81
75	Type 2 diabetes and later cognitive function in older American Indians: The Strong Heart Study. International Journal of Geriatric Psychiatry, 2019, 34, 1050-1057.	2.7	9
76	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
77	Primum non nocere: a call for balance when reporting on CTE. Lancet Neurology, The, 2019, 18, 231-233.	10.2	48
78	S401: IDENTIFYING ELDERS AT RISK FOR COGNITIVE DECLINE USING THE BRAIN HEALTH REGISTRY (BHR). Alzheimer's and Dementia, 2019, 15, P1215.	0.8	0
79	Association Between Sepsis and Microvascular Brain Injury*. Critical Care Medicine, 2019, 47, 1531-1538.	0.9	17
80	Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease. Movement Disorders, 2019, 34, 285-291.	3.9	13
81	A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis. Alzheimer's and Dementia, 2019, 15, 93-105.	0.8	65
82	Mass synaptometry: High-dimensional multi parametric assay for single synapses. Journal of Neuroscience Methods, 2019, 312, 73-83.	2.5	26
83	The associations among sociocultural factors and neuropsychological functioning in older American Indians: The Strong Heart Study.. Neuropsychology, 2019, 33, 1078-1088.	1.3	12
84	Attention Network Test fMRI data for participants with Parkinson's disease and healthy elderly. F1000Research, 2019, 8, 780.	1.6	1
85	Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 50, 29-36.	2.2	94
86	NIA's Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.8	5,861
87	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. Alzheimer's and Dementia, 2018, 14, 563-575.	0.8	98
88	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 463-472.	1.5	41
89	Vasodilator dysfunction and oligodendrocyte dysmaturation in aging white matter. Annals of Neurology, 2018, 83, 142-152.	5.3	25
90	Application of the condensed protocol for the NIA's guidelines for the neuropathological assessment of Alzheimer's disease in an academic clinical practice. Histopathology, 2018, 72, 433-440.	2.9	7

#	ARTICLE	IF	CITATIONS
91	TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1549-1558.	2.6	16
92	The Revised National Alzheimer's Coordinating Center's Neuropathology Form Available Data and New Analyses. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 717-726.	1.7	116
93	Sex-specific genetic predictors of Alzheimer's disease biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 857-872.	7.7	87
94	Genome-wide pleiotropy analysis of neuropathological traits related to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 22.	6.2	27
95	Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. <i>JAMA Neurology</i> , 2018, 75, 989.	9.0	223
96	Exposure to Strong Anticholinergic Medications and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 607-616.	2.6	14
97	Flow Cytometric Evaluation of Crude Synaptosome Preparation as a Way to Study Synaptic Alteration in Neurodegenerative Diseases. <i>Neuromethods</i> , 2018, 141, 297-310.	0.3	5
98	Performance of a Condensed Protocol That Reduces Effort and Cost of NIA-AA Guidelines for Neuropathologic Assessment of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 39-43.	1.7	11
99	Human Striatal Dopaminergic and Regional Serotonergic Synaptic Degeneration with Lewy Body Disease and Inheritance of APOE ϵ 4. <i>American Journal of Pathology</i> , 2017, 187, 884-895.	3.8	12
100	Systems biology approach to late-onset Alzheimer's disease genome-wide association study identifies novel candidate genes validated using brain expression data and <i>Caenorhabditis elegans</i> experiments. , 2017, 13, 1133-1142.		40
101	Transethnic genome-wide scan identifies novel Alzheimer's disease loci. <i>Alzheimer's and Dementia</i> , 2017, 13, 727-738.	0.8	166
102	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 56, 211.e1-211.e7.	3.1	37
103	Resistance to Alzheimer Disease Neuropathologic Changes and Apparent Cognitive Resilience in the Nun and Honolulu-Asia Aging Studies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 458-466.	1.7	61
104	Use of Analgesics (Opioids and Nonsteroidal Anti-Inflammatory Drugs) and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 435-448.	2.6	11
105	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.1	2,805
106	Total Brain and Hippocampal Volumes and Cognition in Older American Indians. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 94-100.	1.3	9
107	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. <i>Lancet Neurology</i> , The, 2017, 16, 55-65.	10.2	394
108	Traumatic brain injury may not increase the risk of Alzheimer disease. <i>Neurology</i> , 2017, 89, 1923-1925.	1.1	54

#	ARTICLE	IF	CITATIONS
109	Neuropathological Comparison of Adult Onset and Juvenile Huntingtonâ€™s Disease with Cerebellar Atrophy: A Report of a Father and Son. Journal of Huntington's Disease, 2017, 6, 337-348.	1.9	23
110	Alzheimer's Disease Sequencing Project discovery and replication criteria for cases and controls: Data from a communityâ€‘based prospective cohort study with autopsy followâ€‘up. Alzheimer's and Dementia, 2017, 13, 1410-1413.	0.8	21
111	Rare coding variants in PLCC2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
112	Homocysteine and cognitive function in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 44, 1-5.	2.2	44
113	[O1â€‘03â€‘06]: IDENTIFICATION OF AN <i>ITGA7</i> VARIANT ASSOCIATED WITH ALZHEIMER'S DISEASE AND MULTIPLE OTHER NEURODEGENERATIVE DISEASES. Alzheimer's and Dementia, 2017, 13, P193.	0.8	0
114	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. Annals of Clinical and Translational Neurology, 2017, 4, 15-25.	3.7	40
115	Regulatory region genetic variation is associated with FYN expression in Alzheimer's disease. Neurobiology of Aging, 2017, 51, 43-53.	3.1	11
116	Effects of Regular and Long-Acting Insulin on Cognition and Alzheimerâ€™s Disease Biomarkers: A Pilot Clinical Trial. Journal of Alzheimer's Disease, 2017, 57, 1325-1334.	2.6	247
117	[P2â€‘383]: COMPARISON OF REGIONAL FLORTAUCIPR PET TO QUANTITATIVE TAU AND AMYLOID IMMUNOASSAY IN PATIENTS WITH ALZHEIMER'S DISEASE PATHOLOGY: A PILOT CLINICOâ€‘PATHOLOGICAL STUDY. Alzheimer's and Dementia, 2017, 13, P776.	0.8	1
118	[P2â€‘432]: IMPAIRMENTS OF MOTOR FUNCTION AS CORRELATES OR HARBINGERS OF DEMENTIA IN THE HONOLULUâ€‘ASIA AGING STUDY. Alzheimer's and Dementia, 2017, 13, P801.	0.8	0
119	[P3â€‘098]: ALZHEIMER'S DISEASE SEQUENCING PROJECT DISCOVERY AND REPLICATION CRITERIA FOR CASES AND CONTROLS: DATA FROM A COMMUNITYâ€‘BASED PROSPECTIVE COHORT STUDY WITH AUTOPSY FOLLOWâ€‘UP. Alzheimer's and Dementia, 2017, 13, P971.	0.8	0
120	Association between Cholesterol Exposure and Neuropathological Findings: The ACT Study. Journal of Alzheimer's Disease, 2017, 59, 1307-1315.	2.6	7
121	An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nature Methods, 2017, 14, 959-962.	19.0	1,653
122	Neuropathological and transcriptomic characteristics of the aged brain. ELife, 2017, 6, .	6.0	97
123	Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults. Alzheimer's Research and Therapy, 2017, 9, 48.	6.2	38
124	Associations between Use of Specific Analgesics and Concentrations of Amyloid-Î² 42 or Phospho-Tau in Regions of Human Cerebral Cortex. Journal of Alzheimer's Disease, 2017, 61, 653-662.	2.6	10
125	Glucocerebrosidase Deficiency in Drosophila Results in Î±-Synuclein-Independent Protein Aggregation and Neurodegeneration. PLoS Genetics, 2016, 12, e1005944.	3.5	261
126	Rhoâ€‘associated protein kinase 1 (<sc>ROCK</sc>1) is increased in Alzheimer's disease and <sc>ROCK</sc>1 depletion reduces amyloidâ€‘Î² levels in brain. Journal of Neurochemistry, 2016, 138, 525-531.	3.9	97

#	ARTICLE	IF	CITATIONS
127	Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings. <i>JAMA Neurology</i> , 2016, 73, 1062.	9.0	337
128	Mitochondrial DNA mutations increase in early stage Alzheimer disease and are inconsistent with oxidative damage. <i>Annals of Neurology</i> , 2016, 80, 301-306.	5.3	78
129	P1â€²71: Dualâ€²Tracer Acetoacetate and Glucose Metabolism are Associated With Neuropathologic Amyloid Burden and Alzheimerâ€²s Biomarkers in The CSF. <i>Alzheimer's and Dementia</i> , 2016, 12, P519.	0.8	1
130	CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1125-1131.	0.8	154
131	Unbiased Stereological Analysis of Reactive Astroglia to Estimate Age-Associated Cerebral White Matter Injury. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 539-554.	1.7	16
132	Multisite assessment of NIAâ€²AA guidelines for the neuropathologic evaluation of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 164-169.	0.8	82
133	Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 516-526.	1.7	67
134	Seedâ€²competent highâ€²molecularâ€²weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients. <i>Annals of Neurology</i> , 2016, 80, 355-367.	5.3	89
135	Shared genetic contribution to ischemic stroke and Alzheimer's disease. <i>Annals of Neurology</i> , 2016, 79, 739-747.	5.3	56
136	The phosphatase calcineurin regulates pathological TDP-43 phosphorylation. <i>Acta Neuropathologica</i> , 2016, 132, 545-561.	7.7	40
137	Association of <i>GBA</i> Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 1217.	9.0	185
138	Glucose levels during life and neuropathologic findings at autopsy among people never treated for diabetes. <i>Neurobiology of Aging</i> , 2016, 48, 72-82.	3.1	13
139	Type 2 Diabetes, Cognition, and Dementia in Older Adults: Toward a Precision Health Approach. <i>Diabetes Spectrum</i> , 2016, 29, 210-219.	1.0	73
140	Importance of home study visit capacity in dementia studies. <i>Alzheimer's and Dementia</i> , 2016, 12, 419-426.	0.8	21
141	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. <i>Acta Neuropathologica</i> , 2016, 131, 87-102.	7.7	380
142	<i>GBA</i> Variants are associated with a distinct pattern of cognitive deficits in <sc>P</sc>arkinson's disease. <i>Movement Disorders</i> , 2016, 31, 95-102.	3.9	158
143	Precision Medicine. <i>American Journal of Pathology</i> , 2016, 186, 500-506.	3.8	49
144	Clinical-pathologic correlations in vascular cognitive impairment and dementia. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 945-951.	3.8	14

#	ARTICLE	IF	CITATIONS
145	P1-209: Cerebral amyloid angiopathy is not associated with late-life cognitive performance in the honolulu asia aging study. , 2015, 11, P430-P431.		0
146	Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF A β 42 and Tau. Journal of Alzheimer's Disease, 2015, 47, 883-887.	2.6	15
147	Multiplexed In-cell Immunoassay for Same-sample Protein Expression Profiling. Scientific Reports, 2015, 5, 13651.	3.3	3
148	Obesity and inflammation markers in relation to leukocyte telomere length in a cross-sectional study of persons with Barrett's esophagus. BMC Obesity, 2015, 2, 32.	3.1	18
149	APOE genotype-dependent modulation of astrocyte chemokine CCL3 production. Glia, 2015, 63, 51-65.	4.9	42
150	Cerebrospinal fluid A β 42 levels and APP processing pathway genes in Parkinson's disease. Movement Disorders, 2015, 30, 936-944.	3.9	14
151	LINGO-1 promotes lysosomal degradation of amyloid- β protein precursor. Pathobiology of Aging & Age Related Diseases, 2015, 5, 25796.	1.1	12
152	Rarity of the Alzheimer Disease "Protective" APP A673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	9.0	41
153	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimer's and Dementia, 2015, 11, 549-560.	0.8	205
154	Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2015, 74, 672-687.	1.7	33
155	P2-029: Dementia and motor impairments: Independent development and neuropathologic substrates in the honolulu-asia aging study (HAAS). , 2015, 11, P492-P492.		0
156	P3-024: Cognitive resilience and vulnerability to Alzheimer brain lesions in the honolulu-asia aging study (HAAS). , 2015, 11, P628-P629.		0
157	O5-04-05: Aerobic exercise reduces phosphorylated tau protein in cerebrospinal fluid in older adults with mild cognitive impairment. , 2015, 11, P324-P324.		6
158	Cognitive profile of LRRK2-related Parkinson's disease. Movement Disorders, 2015, 30, 728-733.	3.9	64
159	Different mechanisms of apolipoprotein E isoform-dependent modulation of prostaglandin E ₂ production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia. FASEB Journal, 2015, 29, 1754-1762.	0.5	44
160	Diagnostic Values of Cerebrospinal Fluid T-Tau and A β 42 using Meso Scale Discovery Assays for Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 709-719.	2.6	28
161	Group comparison of spatiotemporal dynamics of intrinsic networks in Parkinson's disease. Brain, 2015, 138, 2672-2686.	7.6	24
162	Precision medicine: Clarity for the clinical and biological complexity of Alzheimer's and Parkinson's diseases. Journal of Experimental Medicine, 2015, 212, 601-605.	8.5	34

#	ARTICLE	IF	CITATIONS
163	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2015, 129, 757-762.	7.7	139
164	Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of α -synuclein Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2015, 93, 1413-1422.	2.9	13
165	Cerebral Cortical $\text{A}\beta_{42}$ and PHF- τ , in 325 Consecutive Brain Autopsies Stratified by Diagnosis, Location, and APOE ϵ . <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 100-109.	1.7	19
166	Relative contributions of severe dopaminergic neuron ablation and dopamine depletion to cognitive impairment. <i>Experimental Neurology</i> , 2015, 271, 205-214.	4.1	15
167	Characterizing Apolipoprotein E ϵ 4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal $\text{A}\beta_{42}$ -Amyloid Peptide Plaques. <i>JAMA Neurology</i> , 2015, 72, 1124.	9.0	78
168	Convergent genetic and expression data implicate immunity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 658-671.	0.8	173
169	Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 710-717.	0.8	461
170	Prostaglandin E2 Receptor Subtype 2 Regulation of Scavenger Receptor CD36 Modulates Microglial $\text{A}\beta_{42}$ Phagocytosis. <i>American Journal of Pathology</i> , 2015, 185, 230-239.	3.8	31
171	Wild-type bone marrow transplant partially reverses neuroinflammation in progranulin-deficient mice. <i>Laboratory Investigation</i> , 2014, 94, 1224-1236.	3.7	6
172	The Tau Tubulin Kinases TTBK1/2 Promote Accumulation of Pathological TDP-43. <i>PLoS Genetics</i> , 2014, 10, e1004803.	3.5	88
173	Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias. <i>PLoS Genetics</i> , 2014, 10, e1004606.	3.5	305
174	People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. <i>Movement Disorders</i> , 2014, 29, 1258-1264.	3.9	76
175	Aggregates of Small Nuclear Ribonucleic Acids (α -snRNAs) in α -synuclein Alzheimer's Disease. <i>Brain Pathology</i> , 2014, 24, 344-351.	4.1	83
176	Influence of Lifestyle Modifications on Age-Related Free Radical Injury to Brain. <i>JAMA Neurology</i> , 2014, 71, 1150.	9.0	23
177	Inflammation and Oxidative Stress Markers and Esophageal Adenocarcinoma Incidence in a Barrett's Esophagus Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2393-2403.	2.5	35
178	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1394.	9.0	166
179	Cross-Sectional and Longitudinal Relationships Between Cerebrospinal Fluid Biomarkers and Cognitive Function in People Without Cognitive Impairment From Across the Adult Life Span. <i>JAMA Neurology</i> , 2014, 71, 742.	9.0	40
180	APOE ϵ , MAPT, and SNCA Genes and Cognitive Performance in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 1405.	9.0	172

#	ARTICLE	IF	CITATIONS
181	The future of blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 115-131.	0.8	250
182	Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. <i>Biochemical Pharmacology</i> , 2014, 88, 565-572.	4.4	60
183	Gene-based GWAS and biological pathway analysis of the resilience of executive functioning. <i>Brain Imaging and Behavior</i> , 2014, 8, 110-118.	2.1	33
184	Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference. <i>Annals of Neurology</i> , 2014, 76, 469-472.	5.3	75
185	Primary age-related tauopathy (PART): a common pathology associated with human aging. <i>Acta Neuropathologica</i> , 2014, 128, 755-766.	7.7	1,060
186	Recommendations of the Alzheimer's Disease-Related Dementias Conference. <i>Neurology</i> , 2014, 83, 851-860.	1.1	103
187	Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer's disease. <i>Laboratory Investigation</i> , 2014, 94, 1161-1172.	3.7	28
188	Evaluation of mild cognitive impairment subtypes in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 756-764.	3.9	53
189	ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. <i>Acta Neuropathologica</i> , 2014, 127, 825-843.	7.7	70
190	Absence of <i>C9ORF72</i> expanded or intermediate repeats in autopsy-confirmed Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 827-830.	3.9	24
191	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e94661.	2.5	155
192	Low Plasma Leptin in Cognitively Impaired ADNI Subjects: Gender Differences and Diagnostic and Therapeutic Potential. <i>Current Alzheimer Research</i> , 2014, 11, 165-174.	1.4	54
193	Glucose Levels and Risk of Dementia. <i>New England Journal of Medicine</i> , 2013, 369, 540-548.	27.0	696
194	Antagonism of Neuronal Prostaglandin E2 Receptor Subtype 1 Mitigates Amyloid β^2 Neurotoxicity In Vitro. <i>Journal of Neuroimmune Pharmacology</i> , 2013, 8, 87-93.	4.1	13
195	Effect of Apolipoprotein E Genotype and Diet on Apolipoprotein E Lipidation and Amyloid Peptides. <i>JAMA Neurology</i> , 2013, 70, 972.	9.0	85
196	Memory, Mood, and Vitamin D in Persons with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2013, 3, 547-555.	2.8	65
197	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013, 45, 1452-1458.	21.4	3,741
198	Epigenetic signature and enhancer activity of the human APOE gene. <i>Human Molecular Genetics</i> , 2013, 22, 5036-5047.	2.9	59

#	ARTICLE	IF	CITATIONS
199	U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16562-16567.	7.1	268
200	Pharmacologic Inhibition of ROCK2 Suppresses Amyloid- β Production in an Alzheimer's Disease Mouse Model. Journal of Neuroscience, 2013, 33, 19086-19098.	3.6	118
201	Digestion products of the PH20 hyaluronidase inhibit remyelination. Annals of Neurology, 2013, 73, 266-280.	5.3	94
202	APOE ϵ 4 Increases Risk for Dementia in Pure Synucleinopathies. JAMA Neurology, 2013, 70, 223.	9.0	302
203	Perivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantation. Experimental and Molecular Pathology, 2013, 95, 7-17.	2.1	16
204	APOE3, but Not APOE4, Bone Marrow Transplantation Mitigates Behavioral and Pathological Changes in a Mouse Model of Alzheimer Disease. American Journal of Pathology, 2013, 183, 905-917.	3.8	28
205	Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Annals of Neurology, 2013, 74, 119-127.	5.3	116
206	Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease. Experimental and Molecular Pathology, 2013, 94, 366-371.	2.1	28
207	A Randomized Placebo-Controlled Pilot Trial of Omega-3 Fatty Acids and Alpha Lipoic Acid in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 111-120.	2.6	210
208	MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers, 2013, 18, 455-466.	1.9	102
209	Abnormal Gephyrin Immunoreactivity Associated With Alzheimer Disease Pathologic Changes. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1009-1015.	1.7	29
210	Neuropathologic Correlates of Cognition in a Population-Based Sample. Journal of Alzheimer's Disease, 2013, 36, 699-709.	2.6	47
211	Pacific Northwest Udall Center of Excellence Clinical Consortium: Study Design and Baseline Cohort Characteristics. Journal of Parkinson's Disease, 2013, 3, 205-214.	2.8	64
212	Adult Changes in Thought Study: Dementia is an Individually Varying Convergent Syndrome with Prevalent Clinically Silent Diseases that may be Modified by Some Commonly Used Therapeutics. Current Alzheimer Research, 2012, 9, 718-723.	1.4	51
213	Intranasal Insulin Therapy for Alzheimer Disease and Amnesic Mild Cognitive Impairment. Archives of Neurology, 2012, 69, 29.	4.5	1,073
214	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	1.7	1,599
215	Neuropathologic substrates of Parkinson disease dementia. Annals of Neurology, 2012, 72, 587-598.	5.3	401
216	National Institute on Aging's Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, 1-13.	0.8	1,968

#	ARTICLE	IF	CITATIONS
217	Age-Dependent Changes in the Cerebrospinal Fluid Proteome by Slow Off-Rate Modified Aptamer Array. American Journal of Pathology, 2012, 180, 446-456.	3.8	87
218	Inflammatory prostaglandin E ₂ signaling in a mouse model of Alzheimer disease. Annals of Neurology, 2012, 72, 788-798.	5.3	81
219	Eicosanoid receptor subtype ϵ -mediated opposing regulation of TLR α -stimulated expression of astrocyte glial α -derived neurotrophic factor. FASEB Journal, 2012, 26, 3075-3083.	0.5	15
220	Antioxidants for Alzheimer Disease. Archives of Neurology, 2012, 69, 836-41.	4.5	314
221	Genetic architecture of resilience of executive functioning. Brain Imaging and Behavior, 2012, 6, 621-633.	2.1	22
222	Male Microchimerism in the Human Female Brain. PLoS ONE, 2012, 7, e45592.	2.5	91
223	High-Intensity Physical Activity Modulates Diet Effects on Cerebrospinal Amyloid- β Levels in Normal Aging and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2012, 28, 137-146.	2.6	43
224	The genetics and neuropathology of Alzheimer's disease. Acta Neuropathologica, 2012, 124, 305-323.	7.7	203
225	Novel Antibody Capture Assay for Paraffin-Embedded Tissue Detects Wide-Ranging Amyloid Beta and Paired Helical Filament α -Tau Accumulation in Cognitively Normal Older Adults. Brain Pathology, 2012, 22, 472-484.	4.1	22
226	National Institute on Aging α -Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathologica, 2012, 123, 1-11.	7.7	2,002
227	PD biomarkers α -use of β -synuclein reaches new levels. Nature Reviews Neurology, 2011, 7, 308-309.	10.1	1
228	Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy. American Journal of Pathology, 2011, 178, 1509-1516.	3.8	97
229	Prostanoid signaling: Dual role for prostaglandin E2 in neurotoxicity. NeuroToxicology, 2011, 32, 312-319.	3.0	58
230	Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism and Related Disorders, 2011, 17, 61-64.	2.2	64
231	Prevalence Estimates for Latent Neurodegenerative Disease. Toxicologic Pathology, 2011, 39, 99-102.	1.8	8
232	The Effects of Co-Treatment of 9-cis-Retinoic Acid and 15-Deoxy- β (12,14)-prostaglandin J2 on Microglial Activation. Molecules, 2011, 16, 4045-4058.	3.8	0
233	Treatment with a β -Ketoaldehyde Scavenger Prevents Working Memory Deficits in hApoE4 Mice. Journal of Alzheimer's Disease, 2011, 27, 49-59.	2.6	40
234	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	21.4	1,676

#	ARTICLE	IF	CITATIONS
235	Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease. <i>Current Opinion in Neurobiology</i> , 2011, 21, 920-928.	4.2	85
236	Mutations in Prickle Orthologs Cause Seizures in Flies, Mice, and Humans. <i>American Journal of Human Genetics</i> , 2011, 88, 138-149.	6.2	125
237	Increased Cerebrospinal Fluid F2-Isoprostanes are Associated with Aging and Latent Alzheimer's Disease as Identified by Biomarkers. <i>NeuroMolecular Medicine</i> , 2011, 13, 37-43.	3.4	65
238	Role of Cerebrospinal Fluid and Plasma Biomarkers in the Diagnosis of Neurodegenerative Disorders and Mild Cognitive Impairment. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 455-463.	4.2	9
239	Familial prion disease with alzheimer disease-like tau pathology and clinical phenotype. <i>Annals of Neurology</i> , 2011, 69, 712-720.	5.3	67
240	Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. <i>Annals of Neurology</i> , 2011, 69, 570-580.	5.3	371
241	Alternative processing of β -secretase substrates in common forms of mild cognitive impairment and alzheimer's disease: Evidence for β -secretase dysfunction. <i>Annals of Neurology</i> , 2011, 69, 1026-1031.	5.3	40
242	White matter lesions defined by diffusion tensor imaging in older adults. <i>Annals of Neurology</i> , 2011, 70, 465-476.	5.3	104
243	Suppressed microglial E prostanoïd receptor 1 signaling selectively reduces tumor necrosis factor alpha and interleukin 6 secretion from toll-like receptor 3 activation. <i>Glia</i> , 2011, 59, 569-576.	4.9	16
244	Diet Intervention and Cerebrospinal Fluid Biomarkers in Amnestic Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2011, 68, 743-52.	4.5	122
245	Ecology of the Aging Human Brain. <i>Archives of Neurology</i> , 2011, 68, 1049.	4.5	161
246	Apolipoprotein E isoform-dependent microglia migration. <i>FASEB Journal</i> , 2011, 25, 2082-2091.	0.5	46
247	Severely Impaired Learning and Altered Neuronal Morphology in Mice Lacking NMDA Receptors in Medium Spiny Neurons. <i>PLoS ONE</i> , 2011, 6, e28168.	2.5	27
248	Ellsworth C. "Buster" Alvord, Jr. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 663-664.	1.7	0
249	William R. Markesbery, MD. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 767-768.	1.7	0
250	Aberrant Detergent-Insoluble Excitatory Amino Acid Transporter 2 Accumulates in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 667-676.	1.7	59
251	Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment and Dementia. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 301-309.	2.6	17
252	Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. <i>Journal of Neural Transmission</i> , 2010, 117, 227-239.	2.8	48

#	ARTICLE	IF	CITATIONS
253	<i>ε</i> -APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 409-417.	1.7	62
254	Glycoproteomics in neurodegenerative diseases. Mass Spectrometry Reviews, 2010, 29, 79-125.	5.4	99
255	CSF Aβ ₄₂ and tau in Parkinson's disease with cognitive impairment. Movement Disorders, 2010, 25, 2682-2685.	3.9	162
256	Development and application of a comprehensive two-dimensional gas chromatography with time-of-flight mass spectrometry method for the analysis of L-Î ² -methylamino-alanine in human tissue. Journal of Chromatography A, 2010, 1217, 4639-4647.	3.7	64
257	Attenuated progression of diet-induced steatohepatitis in glutathione-deficient mice. Laboratory Investigation, 2010, 90, 1704-1717.	3.7	67
258	Association Between Lifetime Cigarette Smoking and Lewy Body Accumulation. Brain Pathology, 2010, 20, 412-418.	4.1	29
259	Pathologic Correlates of Dementia in Individuals with Lewy Body Disease. Brain Pathology, 2010, 20, 654-659.	4.1	39
260	Cognitive Impairment in Parkinson's Disease. Brain Pathology, 2010, 20, 632-632.	4.1	1
261	Elevated Ratio of Urinary Metabolites of Thromboxane and Prostacyclin Is Associated with Adverse Cardiovascular Events in ADAPT. PLoS ONE, 2010, 5, e9340.	2.5	17
262	The Spectrum of Mutations in Progranulin. Archives of Neurology, 2010, 67, 161-70.	4.5	166
263	Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomarkers in Medicine, 2010, 4, 27-36.	1.4	191
264	The Prostaglandin E2 E-Prostanoid 4 Receptor Exerts Anti-Inflammatory Effects in Brain Innate Immunity. Journal of Immunology, 2010, 184, 7207-7218.	0.8	128
265	Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. Archives of Neurology, 2010, 67, 1473.	4.5	376
266	Morphometric Analysis in Neurodegenerative Disorders. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et al], 2010, 46, 12.16.1.	1.1	4
267	DJ-1 and Î±-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain, 2010, 133, 713-726.	7.6	575
268	Quantitative Proteomic Analysis of Oligodendrogliomas With and Without 1p/19q Deletion. Journal of Proteome Research, 2010, 9, 2610-2618.	3.7	12
269	Diabetes and Insulin in Regulation of Brain Cholesterol Metabolism. Cell Metabolism, 2010, 12, 567-579.	16.2	145
270	Suppressed Accumulation of Cerebral Amyloid Î² Peptides in Aged Transgenic Alzheimer's Disease Mice by Transplantation with Wild-Type or Prostaglandin E2 Receptor Subtype 2-Null Bone Marrow. American Journal of Pathology, 2010, 177, 346-354.	3.8	53

#	ARTICLE	IF	CITATIONS
271	Neuropathology-Based Risk Scoring for Dementia Diagnosis in the Elderly. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 875-885.	2.6	13
272	Modulation of Microglial Innate Immunity in Alzheimers Disease by Activation of Peroxisome Proliferator-activated Receptor Gamma. <i>Current Medicinal Chemistry</i> , 2009, 16, 643-651.	2.4	37
273	Depletion of B Lymphocytes From Cerebral Perivascular Spaces by Rituximab. <i>Archives of Neurology</i> , 2009, 66, 1016-20.	4.5	66
274	Cognitive Impairment in Older Adults Without Dementia: Clinical and Pathologic Outcomes in a Community-Based Sample. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2009, 22, 256-265.	2.3	8
275	Different Patterns of Cerebral Injury in Dementia With or Without Diabetes. <i>Archives of Neurology</i> , 2009, 66, 315.	4.5	199
276	Parkinsonâ€™dementia complex and development of a new stable isotope dilution assay for BMAA detection in tissue. <i>Toxicology and Applied Pharmacology</i> , 2009, 240, 180-188.	2.8	33
277	A patient with Huntingtonâ€™s disease and long-surviving fetal neural transplants that developed mass lesions. <i>Acta Neuropathologica</i> , 2009, 117, 329-338.	7.7	89
278	Detergentâ€insoluble EAAC1/EAAT3 Aberrantly Accumulates in Hippocampal Neurons of Alzheimer's Disease Patients. <i>Brain Pathology</i> , 2009, 19, 267-278.	4.1	45
279	Quantitation and Mapping of Cerebral Detergentâ€insoluble Proteins in the Elderly. <i>Brain Pathology</i> , 2009, 19, 365-374.	4.1	17
280	Blood Pressure and Brain Injury in Older Adults: Findings from a Communityâ€Based Autopsy Study. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 1975-1981.	2.6	54
281	Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation. <i>European Journal of Neuroscience</i> , 2009, 30, 207-216.	2.6	45
282	Identification of Glutathione S-Transferase Pi as a Protein Involved in Parkinson Disease Progression. <i>American Journal of Pathology</i> , 2009, 175, 54-65.	3.8	75
283	Protection of Hippocampal Neurogenesis from Toll-Like Receptor 4-Dependent Innate Immune Activation by Ablation of Prostaglandin E2 Receptor Subtype EP1 or EP2. <i>American Journal of Pathology</i> , 2009, 174, 2300-2309.	3.8	31
284	DOCK2 Is a Microglial Specific Regulator of Central Nervous System Innate Immunity Found in Normal and Alzheimerâ€™s Disease Brain. <i>American Journal of Pathology</i> , 2009, 175, 1622-1630.	3.8	48
285	Visual Hallucinations in Dementia: A Prospective Community-Based Study With Autopsy. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 317-323.	1.2	29
286	Associations Between Microinfarcts and Other Macroscopic Vascular Findings on Neuropathologic Examination in 2 Databases. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 291-294.	1.3	54
287	Neuropathology in the Adult Changes in Thought Study: A Review. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 703-711.	2.6	65
288	Treatment of latent stage Alzheimerâ€™s disease with statins?. <i>Aging Health</i> , 2009, 5, 29-32.	0.3	1

#	ARTICLE	IF	CITATIONS
289	Late-Life Dementias: Does This Unyielding Global Challenge Require a Broader View?. JAMA - Journal of the American Medical Association, 2009, 302, 2593-2594.	7.4	28
290	Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor and Cognitive Function in Non-Demented Subjects. PLoS ONE, 2009, 4, e5424.	2.5	112
291	Cognitive impairment and dementia in patients with Parkinson disease. Current Topics in Medicinal Chemistry, 2009, 9, 903-12.	2.1	58
292	Cysteine and mercapturate conjugates of oxidized dopamine are in human striatum but only the cysteine conjugate impedes dopamine trafficking in vitro and in vivo. Journal of Neurochemistry, 2008, 79, 510-521.	3.9	21
293	RESEARCH ARTICLE: Empiric Refinement of the Pathologic Assessment of Lewy-Related Pathology in the Dementia Patient. Brain Pathology, 2008, 18, 220-224.	4.1	106
294	70-YEAR-OLD MAN WITH ENLARGED PINEAL GLAND. Brain Pathology, 2008, 18, 602-604.	4.1	1
295	Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radical Biology and Medicine, 2008, 45, 219-230.	2.9	95
296	TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurology, The, 2008, 7, 409-416.	10.2	636
297	Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurology, The, 2008, 7, 704-714.	10.2	85
298	Electrophilic Cyclopentenone Neuroprostanes Are Anti-inflammatory Mediators Formed from the Peroxidation of the ω -3 Polyunsaturated Fatty Acid Docosahexaenoic Acid. Journal of Biological Chemistry, 2008, 283, 19927-19935.	3.4	122
299	Pharmacologic suppression of oxidative damage and dendritic degeneration following kainic acid-induced excitotoxicity in mouse cerebrum. NeuroToxicology, 2008, 29, 621-627.	3.0	50
300	Translational gene mapping of cognitive decline. Neurobiology of Aging, 2008, 29, 524-541.	3.1	28
301	Proteomics of Human Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2008, 67, 923-932.	1.7	31
302	Application of Targeted Quantitative Proteomics Analysis in Human Cerebrospinal Fluid Using a Liquid Chromatography Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Tandem Mass Spectrometer (LC MALDI TOF/TOF) Platform. Journal of Proteome Research, 2008, 7, 720-730.	3.7	67
303	F2-Dihomo-isoprostanes arise from free radical attack on adrenic acid. Journal of Lipid Research, 2008, 49, 995-1005.	4.2	66
304	CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases. American Journal of Clinical Pathology, 2008, 129, 526-529.	0.7	248
305	Therapeutic Targets in Prostaglandin E2 Signaling for Neurologic Disease. Current Medicinal Chemistry, 2008, 15, 1863-1869.	2.4	88
306	Multiplex Immunoassay Analysis of Cytokines in Idiopathic Inflammatory Myopathy. Archives of Pathology and Laboratory Medicine, 2008, 132, 232-238.	2.5	27

#	ARTICLE	IF	CITATIONS
307	Surgical Neuropathology Update: A Review of Changes Introduced by the <i>WHO Classification of Tumours of the Central Nervous System,</i> 4th Edition. Archives of Pathology and Laboratory Medicine, 2008, 132, 993-1007.	2.5	109
308	Biomarkers for Alzheimer's disease. Expert Review of Neurotherapeutics, 2007, 7, 1021-1028.	2.8	14
309	Chronic dietary α -lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiology of Aging, 2007, 28, 213-225.	3.1	155
310	Quantitative Proteomics Identifies Surfactant-Resistant α -Synuclein in Cerebral Cortex of Parkinsonism-Dementia Complex of Guam but Not Alzheimer's Disease or Progressive Supranuclear Palsy. American Journal of Pathology, 2007, 171, 993-1002.	3.8	23
311	Mitochondrial Effects of Lipid-Derived Neurotoxins. Journal of Alzheimer's Disease, 2007, 12, 185-193.	2.6	32
312	Washington statewide pathology surveillance for prion disease. Annals of Neurology, 2007, 61, 371-372.	5.3	4
313	Pathological correlates of dementia in a longitudinal, population-based sample of aging. Annals of Neurology, 2007, 62, 406-413.	5.3	380
314	A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics, 2007, 7, 469-473.	2.2	111
315	Proteomic Identification of Novel Proteins in Cortical Lewy Bodies. Brain Pathology, 2007, 17, 139-145.	4.1	194
316	Effects of chemical chaperones on oxidative stress and detergent-insoluble species formation following conditional expression of amyloid precursor protein carboxy-terminal fragment. Neurobiology of Disease, 2007, 25, 427-437.	4.4	38
317	Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathologica, 2007, 114, 221-229.	7.7	378
318	F2-Isoprostanes as Biomarkers of Late-onset Alzheimer's Disease. Journal of Molecular Neuroscience, 2007, 33, 114-119.	2.3	60
319	Characterization of Proteome of Human Cerebrospinal Fluid. International Review of Neurobiology, 2006, 73, 29-98.	2.0	28
320	Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 8, 359-367.	2.6	20
321	Lewy body pathology in late-onset familial Alzheimer's disease: A clinicopathological case series. Journal of Alzheimer's Disease, 2006, 9, 235-242.	2.6	25
322	Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. Journal of Alzheimer's Disease, 2006, 10, 399-406.	2.6	97
323	LR11/SorLA Expression Is Reduced in Sporadic Alzheimer Disease but not in Familial Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2006, 65, 866-872.	1.7	131
324	Lewy Body Pathology in Familial Alzheimer Disease. Archives of Neurology, 2006, 63, 370.	4.5	122

#	ARTICLE	IF	CITATIONS
325	Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 293-348.	2.6	362
326	Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases. <i>Journal of Alzheimer's Disease</i> , 2006, 8, 377-386.	2.6	55
327	PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42. <i>Journal of Neurochemistry</i> , 2006, 96, 917-923.	3.9	41
328	Liquid chromatography with tandem mass spectrometry-based proteomic discovery in aging and Alzheimer's disease. <i>NeuroRx</i> , 2006, 3, 336-343.	6.0	22
329	Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation. <i>Free Radical Biology and Medicine</i> , 2006, 40, 689-697.	2.9	150
330	Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2006, 19, 195-201.	2.3	20
331	Neurotoxicity from innate immune response is greatest with targeted replacement of ϵ 4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK. <i>FASEB Journal</i> , 2006, 20, 797-799.	0.5	91
332	Selectively increased oxidative modifications mapped to detergent-insoluble forms of $A\beta$ and τ tubulin in Alzheimer's disease. <i>FASEB Journal</i> , 2006, 20, 1473-1483.	0.5	29
333	Brain site-specific determination of protein solubility in Alzheimer's disease. <i>FASEB Journal</i> , 2006, 20, .	0.5	1
334	Liquid chromatography with tandem mass spectrometry-based proteomic discovery in aging and Alzheimer's disease. <i>Neurotherapeutics</i> , 2006, 3, 336-343.	4.4	0
335	Diminished taxol/GTP-stimulated tubulin polymerization in diseased region of brain from patients with late-onset or inherited Alzheimer's disease or frontotemporal dementia with parkinsonism linked to chromosome-17 but not individuals with mild cognitive impairment. <i>Journal of Alzheimer's Disease</i> , 2005, 8, 1-6.	2.6	8
336	Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. <i>Journal of Alzheimer's Disease</i> , 2005, 7, 125-133.	2.6	160
337	Hyperinsulinemia Provokes Synchronous Increases in Central Inflammation and $A\beta$ -Amyloid in Normal Adults. <i>Archives of Neurology</i> , 2005, 62, 1539-44.	4.5	190
338	Suppression of murine cerebral F2-isoprostanes and F4-neuroprostanes from excitotoxicity and innate immune response in vivo by α - or β -tocopherol. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 827, 88-93.	2.3	50
339	Carbofuran-induced oxidative stress in slow and fast skeletal muscles: prevention by memantine and atropine. <i>Toxicology</i> , 2005, 208, 13-24.	4.2	60
340	Role of glutathione in intracellular amyloid-alpha precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity. <i>Journal of Neurochemistry</i> , 2005, 93, 1047-1056.	3.9	53
341	Prostaglandin H_2 -derived adducts of proteins correlate with Alzheimer's disease severity. <i>Journal of Neurochemistry</i> , 2005, 94, 1140-1145.	3.9	60
342	Mechanisms of 4-hydroxynonenal-induced neuronal microtubule dysfunction. <i>Brain Research</i> , 2005, 1037, 90-98.	2.2	59

#	ARTICLE	IF	CITATIONS
343	Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. <i>Glia</i> , 2005, 52, 70-77.	4.9	110
344	Selective vulnerability of preterm white matter to oxidative damage defined by F ₂ -isoprostanes. <i>Annals of Neurology</i> , 2005, 58, 108-120.	5.3	216
345	Î±-Tocopherol disappearance is faster in cigarette smokers and is inversely related to their ascorbic acid status. <i>American Journal of Clinical Nutrition</i> , 2005, 81, 95-103.	4.7	106
346	Proteomic determination of widespread detergent insolubility, including AÎ² but not tau, early in the pathogenesis of Alzheimer's disease. <i>FASEB Journal</i> , 2005, 19, 1923-1925.	0.5	46
347	Deletion of the Prostaglandin E2 EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2005, 25, 10180-10187.	3.6	221
348	F ₂ -Isoprostanes in Alzheimer and Other Neurodegenerative Diseases. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 269-275.	5.4	106
349	Lack of Î±-methylamino-l-alanine in brain from controls, AD, or Chamorros with PDC. <i>Neurology</i> , 2005, 65, 768-769.	1.1	101
350	Microglia Lacking E Prostanoid Receptor Subtype 2 Have Enhanced AÎ² Phagocytosis yet Lack AÎ²-Activated Neurotoxicity. <i>American Journal of Pathology</i> , 2005, 166, 1163-1172.	3.8	116
351	Fatty Acid Oxidation in the Pathogenesis of Alzheimer's Disease. <i>American Journal of Pathology</i> , 2005, 166, 1283-1289.	3.8	101
352	Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2005, 26, 207-227.	3.1	162
353	Microglial EP2 as a New Target to Increase Amyloid Î² Phagocytosis and Decrease Amyloid Î²-Induced Damage to Neurons. <i>Brain Pathology</i> , 2005, 15, 134-138.	4.1	37
354	HIV associated neurodegeneration requires p53 in neurons and microglia. <i>FASEB Journal</i> , 2004, 18, 1141-1143.	0.5	123
355	Analysis of Î±-Synuclein-associated Proteins by Quantitative Proteomics. <i>Journal of Biological Chemistry</i> , 2004, 279, 39155-39164.	3.4	149
356	4Î±-Hydroxy-2-trans-2â€œnonenoic acid is a Î³-hydroxybutyrate receptor ligand in the cerebral cortex and hippocampus. <i>Journal of Neurochemistry</i> , 2004, 89, 1462-1470.	3.9	16
357	Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F2-isoprostanes in the absence of detectable amyloid deposits. <i>Journal of Neurochemistry</i> , 2004, 90, 1011-1018.	3.9	40
358	Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity. <i>Journal of Neurochemistry</i> , 2004, 91, 1312-1321.	3.9	42
359	Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. <i>Chemistry and Physics of Lipids</i> , 2004, 128, 117-124.	3.2	222
360	Quantification of F-ring isoprostane-like compounds (F4-neuroprostanes) derived from docosahexaenoic acid in vivo in humans by a stable isotope dilution mass spectrometric assay. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 799, 95-102.	2.3	70

#	ARTICLE	IF	CITATIONS
361	Oxidized Low-Density Lipoprotein Is Present in Astrocytes Surrounding Cerebral Infarcts and Stimulates Astrocyte Interleukin-6 Secretion. <i>American Journal of Pathology</i> , 2004, 164, 1173-1181.	3.8	48
362	Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2004, 6, 93-97.	2.6	88
363	Advanced glycation endproduct precursor alters intracellular amyloid- β /A β PP carboxy-terminal fragment aggregation and cytotoxicity. <i>Journal of Alzheimer's Disease</i> , 2004, 5, 467-476.	2.6	61
364	Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy. <i>Acta Neuropathologica</i> , 2003, 106, 243-250.	7.7	36
365	Antioxidants significantly affect the formation of different classes of isoprostanes and neuroprostanes in rat cerebral synaptosomes. <i>Biochemical Pharmacology</i> , 2003, 65, 611-617.	4.4	36
366	Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. <i>Journal of Neuroimmunology</i> , 2003, 137, 32-41.	2.3	117
367	Manganese ethylenebis(ethiocarbamate) and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. <i>Journal of Neurochemistry</i> , 2003, 84, 336-346.	3.9	201
368	Pharmacologic suppression of neuronal oxidative damage and dendritic degeneration following direct activation of glial innate immunity in mouse cerebrum. <i>Journal of Neurochemistry</i> , 2003, 87, 1518-1526.	3.9	96
369	Mercapturate Metabolism of 4-Hydroxy-2-Nonenal in Rat and Human Cerebrum. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 146-153.	1.7	26
370	Overview: Membrane lipid peroxidation. <i>Advances in Cell Aging and Gerontology</i> , 2003, 12, 11-26.	0.1	2
371	Combined deficiency of vitamins E and C causes paralysis and death in guinea pigs. <i>American Journal of Clinical Nutrition</i> , 2003, 77, 1484-1488.	4.7	44
372	Mitochondrial DNA Deletions/Rearrangements in Parkinson Disease and Related Neurodegenerative Disorders. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 634-639.	1.7	103
373	Effects of reactive β -ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function. <i>FASEB Journal</i> , 2002, 16, 715-717.	0.5	101
374	Cerebrospinal fluid lipoprotein delivery to human neuronal cells is increased in Alzheimer's disease and is dependent on apoE monomer concentration. <i>Journal of Alzheimer's Disease</i> , 2002, 4, 19-30.	2.6	2
375	Synthesis and Cellular Effects of an Intracellularly Activated Analogue of 4-Hydroxynonenal. <i>Chemical Research in Toxicology</i> , 2002, 15, 40-47.	3.3	15
376	Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. <i>Neuroscience Letters</i> , 2002, 319, 25-28.	2.1	164
377	Mouse cerebral prostaglandins, but not oxidative damage, change with age and are responsive to indomethacin treatment. <i>Brain Research</i> , 2002, 930, 75-82.	2.2	14
378	Lipid peroxidation in aging brain and Alzheimer's disease ^{1,2} Guest Editors: Mark A. Smith and George Perry This article is part of a series of reviews on "Causes and Consequences of Oxidative Stress in Alzheimer's Disease." The full list of papers may be found on the homepage of the journal.. <i>Free Radical Biology and Medicine</i> , 2002, 33, 620-626.	2.9	406

#	ARTICLE	IF	CITATIONS
379	Catalysis of catechol oxidation by metal-dithiocarbamate complexes in pesticides. Free Radical Biology and Medicine, 2002, 33, 1714-1723.	2.9	87
380	Peripheral F ₂ -isoprostanes and F ₄ -neuroprostanes are not increased in Alzheimer's disease. Annals of Neurology, 2002, 52, 175-179.	5.3	156
381	Prostaglandin H2 (PGH2) accelerates formation of amyloid β 1~42 oligomers. Journal of Neurochemistry, 2002, 82, 1003-1006.	3.9	58
382	Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. Journal of Neurochemistry, 2002, 83, 463-470.	3.9	127
383	Carbonyl Toxicology and Alzheimer's Disease. Toxicology and Applied Pharmacology, 2002, 184, 187-197.	2.8	188
384	Formation of Highly Reactive A-ring and J-ring Isoprostane-like Compounds (A4/J4-neuroprostanes) in Vivo from Docosahexaenoic Acid. Journal of Biological Chemistry, 2002, 277, 36076-36084.	3.4	80
385	Dopamine thioethers: Formation in brain and neurotoxicity. Neurotoxicity Research, 2002, 4, 663-669.	2.7	8
386	Herpes simplex virus type 1 encephalitis is associated with elevated levels of F 2 -isoprostanes and F 4 -neuroprostanes. Journal of NeuroVirology, 2002, 8, 295-305.	2.1	49
387	Formation of Novel D-Ring and E-Ring Isoprostane-Like Compounds (D4/E4-Neuroprostanes)in Vivo From Docosahexaenoic Acid. Advances in Experimental Medicine and Biology, 2002, 507, 519-524.	1.6	3
388	Brain Regional Quantification of F-Ring and D-/E-Ring Isoprostanes and Neuroprostanes in Alzheimerâ€™s Disease. American Journal of Pathology, 2001, 158, 293-297.	3.8	167
389	Improved assay for the quantification of the major urinary metabolite of the isoprostane 15-F2t-Isoprostane (8-iso-PGF2Î±) by a stable isotope dilution mass spectrometric assay. Clinica Chimica Acta, 2001, 314, 93-99.	1.1	43
390	Interactions between Apolipoprotein E Gene and Dietary Î±-Tocopherol Influence Cerebral Oxidative Damage in Aged Mice. Journal of Neuroscience, 2001, 21, 5993-5999.	3.6	32
391	Ultrastructure of Striatal Dopamine Synapses in Rats with Striatal Dopamine Depletion. Microscopy and Microanalysis, 2001, 7, 660-661.	0.4	0
392	Expression and Activities of Aldo-Keto Oxidoreductases in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2001, 60, 686-695.	1.7	80
393	4-Hydroxy-2(E)-Nonenal Inhibits CNS Mitochondrial Respiration at Multiple Sites. Journal of Neurochemistry, 2001, 72, 1617-1624.	3.9	140
394	Elevation of AKR7A2 (succinic semialdehyde reductase) in neurodegenerative disease. Brain Research, 2001, 916, 229-238.	2.2	56
395	Expression of glutathione-S-transferase isozyme in the SY5Y neuroblastoma cell line increases resistance to oxidative stress. Free Radical Biology and Medicine, 2001, 31, 73-81.	2.9	53
396	Formation of Highly Reactive Î³-Ketoaldehydes (Neuroketals) as Products of the Neuroprostane Pathway. Journal of Biological Chemistry, 2001, 276, 30964-30970.	3.4	90

#	ARTICLE	IF	CITATIONS
397	Cerebrospinal Fluid A β 42, Tau, and F2-Isoprostane Concentrations in Patients With Alzheimer Disease, Other Dementias, and in Age-Matched Controls. Archives of Pathology and Laboratory Medicine, 2001, 125, 510-512.	2.5	106
398	Immunohistochemical and Biochemical Studies Demonstrate a Distinct Profile of α -Synuclein Permutations in Multiple System Atrophy. Journal of Neuropathology and Experimental Neurology, 2000, 59, 830-841.	1.7	135
399	Enhanced N-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Toxicity in Mice Deficient in CuZn-Superoxide Dismutase or Glutathione Peroxidase. Journal of Neuropathology and Experimental Neurology, 2000, 59, 53-61.	1.7	106
400	Cerebrospinal fluid lipoproteins in Alzheimer's disease. Microscopy Research and Technique, 2000, 50, 282-286.	2.2	24
401	Enhancement of Dopaminergic Neurotoxicity by the Mercapturate of Dopamine. Journal of Neurochemistry, 2000, 74, 970-978.	3.9	28
402	Congeners of N α -acetyl-L-cysteine but not aminoguanidine act as neuroprotectants from the lipid peroxidation product 4-hydroxy-2-nonenal. Free Radical Biology and Medicine, 2000, 29, 1028-1036.	2.9	27
403	DOPAMINE MERCAPTURATE CAN AUGMENT DOPAMINERGIC NEURODEGENERATION*. Drug Metabolism Reviews, 2000, 32, 363-376.	3.6	11
404	RNA Oxidation in Alzheimer and Parkinson Diseases. Rejuvenation Research, 1999, 2, 227-230.	0.2	10
405	Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer's disease and are neurotoxic when oxidized ex vivo. Lipids, 1999, 34, 1273-1280.	1.7	54
406	Endogenous catechol thioethers may be pro-oxidant or antioxidant. Free Radical Biology and Medicine, 1999, 27, 271-277.	2.9	32
407	High-Pressure Liquid Chromatography Quantitation of Cytochrome c Using 393 nm Detection. Analytical Biochemistry, 1999, 276, 166-170.	2.4	28
408	The Magnitude of Brain Lipid Peroxidation Correlates with the Extent of Degeneration but Not with Density of Neuritic Plaques or Neurofibrillary Tangles or with APOE Genotype in Alzheimer's Disease Patients. American Journal of Pathology, 1999, 155, 863-868.	3.8	108
409	Parkinson's Disease Is Associated with Oxidative Damage to Cytoplasmic DNA and RNA in Substantia Nigra Neurons. American Journal of Pathology, 1999, 154, 1423-1429.	3.8	570
410	Divergence of Brain Prostaglandin H Synthase Activity and Oxidative Damage in Mice with Encephalitis. Journal of Neuropathology and Experimental Neurology, 1999, 58, 1269-1275.	1.7	8
411	Reactions of 4-Hydroxy-2(E)-nonenal and Related Aldehydes with Proteins Studied by Carbon-13 Nuclear Magnetic Resonance Spectroscopy. Chemical Research in Toxicology, 1998, 11, 317-328.	3.3	53
412	Secondary Excitotoxicity Contributes to Dopamine-Induced Apoptosis of Dopaminergic Neuronal Cultures. Biochemical and Biophysical Research Communications, 1998, 248, 812-816.	2.1	51
413	Formation of Isoprostane-like Compounds (Neuroprostanes) in Vivo from Docosahexaenoic Acid. Journal of Biological Chemistry, 1998, 273, 13605-13612.	3.4	377
414	Distribution of Reducible 4-Hydroxynonenal Adduct Immunoreactivity in Alzheimer Disease is Associated with APOE Genotype. Journal of Neuropathology and Experimental Neurology, 1998, 57, 415-425.	1.7	137

#	ARTICLE	IF	CITATIONS
415	Refractory status epilepticus associated with progressive magnetic resonance imaging signal change and hippocampal neuronal loss. Journal of Epilepsy, 1996, 9, 253-258.	0.4	21
416	Crosslinking of Apolipoprotein E by Products of Lipid Peroxidation. Journal of Neuropathology and Experimental Neurology, 1996, 55, 202-210.	1.7	80
417	Covalent Crosslinking of Neurofilament Proteins by Oxidized Catechols as a Potential Mechanism of Lewy Body Formation. Journal of Neuropathology and Experimental Neurology, 1995, 54, 311-319.	1.7	51
418	Vascular Malformations Presenting as Spinal Cord Neoplasms: Case Report. Neurosurgery, 1995, 36, 194-198.	1.1	13
419	Dialkyldithiocarbamates inhibit tyrosine hydroxylase activity in PC12 cells and in fibroblasts that express tyrosine hydroxylase. Experimental Neurology, 1995, 4, 283-290.	1.7	11
420	Prognostic Significance of Ki-67 Proliferation Index in Supratentorial Fibrillary Astrocytic Neoplasms. Neurosurgery, 1994, 34, 674-679.	1.1	96
421	Renal toxicity of antineoplastic agents. Toxicology Letters, 1990, 53, 93-96.	0.8	1
422	Role of endogenous sulfur-containing nucleophiles in an in vitro model of cis-diamminedichloroplatinum(II)-induced nephrotoxicity. Biochemical Pharmacology, 1990, 39, 1751-1757.	4.4	36
423	High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations. Cancer Chemotherapy and Pharmacology, 1989, 23, 276-278.	2.3	21
424	Targeting LRRK2 mutations in Parkinson's disease. Future Medicinal Chemistry, 0, , .	2.3	1